Acrivon Therapeutics: Priced For Failure, Built For Precision

Impact · against what's priced in

ACRV presents a deep-value opportunity as it trades below its cash value while possessing high-efficacy data (50% response rate) in serous endometrial cancer. The stock is positioned for significant upside if upcoming Phase 2b and Phase 1 data readouts validate the platform's precision matching capabilities.

ACRV+0.70

No priced-in read yet

In context

The 50% response rate for ACR-368 in serous endometrial cancer and the fact that the company trades below its cash value provide a strong valuation floor and immediate catalyst potential.

Read from the article alone

• biotech
• ACRV
• cancer research
• clinical trials
• kinase inhibitors
• oncology
• pipeline
• precision medicine
• undervalued

Search tags